These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 10651600)

  • 1. Discontinuation of chemoprophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection. HIV Outpatient Study (HOPS) Investigators.
    Yangco BG; Von Bargen JC; Moorman AC; Holmberg SD
    Ann Intern Med; 2000 Feb; 132(3):201-5. PubMed ID: 10651600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group.
    Weverling GJ; Mocroft A; Ledergerber B; Kirk O; Gonzáles-Lahoz J; d'Arminio Monforte A; Proenca R; Phillips AN; Lundgren JD; Reiss P
    Lancet; 1999 Apr; 353(9161):1293-8. PubMed ID: 10218526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?
    ; Mocroft A; Reiss P; Kirk O; Mussini C; Girardi E; Morlat P; Stephan C; De Wit S; Doerholt K; Ghosn J; Bucher HC; Lundgren JD; Chene G; Miro JM; Furrer H
    Clin Infect Dis; 2010 Sep; 51(5):611-9. PubMed ID: 20645862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pneumocystis carinii pneumonia incidence and chemoprophylaxis failure in ambulatory HIV-infected patients. HIV Outpatient Study (HOPS) Investigators.
    Moorman AC; Von Bargen JC; Palella FJ; Holmberg SD
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Oct; 19(2):182-8. PubMed ID: 9768629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy.
    Schneider MM; Borleffs JC; Stolk RP; Jaspers CA; Hoepelman AI
    Lancet; 1999 Jan; 353(9148):201-3. PubMed ID: 9923876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective study of discontinuing primary and secondary Pneumocystis carinii pneumonia prophylaxis after CD4 cell count increase to > 200 x 106 /l.
    Koletar SL; Heald AE; Finkelstein D; Hafner R; Currier JS; McCutchan JA; Vallee M; Torriani FJ; Powderly WG; Fass RJ; Murphy RL;
    AIDS; 2001 Aug; 15(12):1509-15. PubMed ID: 11504983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study.
    Furrer H; Egger M; Opravil M; Bernasconi E; Hirschel B; Battegay M; Telenti A; Vernazza PL; Rickenbach M; Flepp M; Malinverni R
    N Engl J Med; 1999 Apr; 340(17):1301-6. PubMed ID: 10219064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups.
    Ledergerber B; Mocroft A; Reiss P; Furrer H; Kirk O; Bickel M; Uberti-Foppa C; Pradier C; D'Arminio Monforte A; Schneider MM; Lundgren JD;
    N Engl J Med; 2001 Jan; 344(3):168-74. PubMed ID: 11188837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98.
    Lopez Bernaldo de Quiros JC; Miro JM; Peña JM; Podzamczer D; Alberdi JC; Martínez E; Cosin J; Claramonte X; Gonzalez J; Domingo P; Casado JL; Ribera E;
    N Engl J Med; 2001 Jan; 344(3):159-67. PubMed ID: 11172138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pneumocystis carinii pneumonia recurrence in HIV patients on highly active antiretroviral therapy: secondary prophylaxis.
    Abgrall S; Matheron S; Le Moing V; Dupont C; Costagliola D;
    J Acquir Immune Defic Syndr; 2001 Feb; 26(2):151-8. PubMed ID: 11242182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pneumocystis jiroveci pneumonia prophylaxis is not required with a CD4+ T-cell count < 200 cells/microl when viral replication is suppressed.
    D'Egidio GE; Kravcik S; Cooper CL; Cameron DW; Fergusson DA; Angel JB
    AIDS; 2007 Aug; 21(13):1711-5. PubMed ID: 17690568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylaxis against Pneumocystis carinii pneumonia among children with perinatally acquired human immunodeficiency virus infection in the United States. Pneumocystis carinii Pneumonia Prophylaxis Evaluation Working Group.
    Simonds RJ; Lindegren ML; Thomas P; Hanson D; Caldwell B; Scott G; Rogers M
    N Engl J Med; 1995 Mar; 332(12):786-90. PubMed ID: 7862183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surveillance for AIDS-defining opportunistic illnesses, 1992-1997.
    Jones JL; Hanson DL; Dworkin MS; Alderton DL; Fleming PL; Kaplan JE; Ward J
    MMWR CDC Surveill Summ; 1999 Apr; 48(2):1-22. PubMed ID: 12412613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discontinuation of secondary prophylaxis for Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients: a randomized trial by the CIOP Study Group.
    Mussini C; Pezzotti P; Antinori A; Borghi V; Monforte Ad; Govoni A; De Luca A; Ammassari A; Mongiardo N; Cerri MC; Bedini A; Beltrami C; Ursitti MA; Bini T; Cossarizza A; Esposito R;
    Clin Infect Dis; 2003 Mar; 36(5):645-51. PubMed ID: 12594647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Failure to prescribe pneumocystis prophylaxis is associated with increased mortality, even in the cART era: results from the Treat Asia HIV observational database.
    Lim PL; Zhou J; Ditangco RA; Law MG; Sirisanthana T; Kumarasamy N; Chen YM; Phanuphak P; Lee CK; Saphonn V; Oka S; Zhang F; Choi JY; Pujari S; Kamarulzaman A; Li PC; Merati TP; Yunihastuti E; Messerschmidt L; Sungkanuparph S;
    J Int AIDS Soc; 2012 Jan; 15(1):1. PubMed ID: 22281054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy?
    Kirk O; Lundgren JD; Pedersen C; Nielsen H; Gerstoft J
    AIDS; 1999 Sep; 13(13):1647-51. PubMed ID: 10509565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1995 revised guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with or perinatally exposed to human immunodeficiency virus. National Pediatric and Family HIV Resource Center and National Center for Infectious Diseases, Centers for Disease Control and Prevention.
    MMWR Recomm Rep; 1995 Apr; 44(RR-4):1-11. PubMed ID: 7565543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discontinuation of Pneumocystis jirovecii pneumonia prophylaxis with CD4 count <200 cells/µL and virologic suppression: a systematic review.
    Costiniuk CT; Fergusson DA; Doucette S; Angel JB
    PLoS One; 2011; 6(12):e28570. PubMed ID: 22194853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discontinuing Pneumocystis jirovecii Pneumonia Prophylaxis in HIV-Infected Patients With a CD4 Cell Count <200 cells/mm3.
    Sidhu VK; Foisy MM; Hughes CA
    Ann Pharmacother; 2015 Dec; 49(12):1343-8. PubMed ID: 26358129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discontinuation of primary prophylaxis in HIV-infected patients at high risk of Pneumocystis carinii pneumonia: prospective multicentre study.
    Furrer H; Opravil M; Rossi M; Bernasconi E; Telenti A; Bucher H; Schiffer V; Boggian K; Rickenbach M; Flepp M; Egger M;
    AIDS; 2001 Mar; 15(4):501-7. PubMed ID: 11242147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.